Discovery of High-Affinity Noncovalent Allosteric KRAS Inhibitors That Disrupt Effector Binding

[Image: see text] Approximately 15% of all human tumors harbor mutant KRAS, a membrane-associated small GTPase and notorious oncogene. Mutations that render KRAS constitutively active will lead to uncontrolled cell growth and cancer. However, despite aggressive efforts in recent years, there are no...

Descripción completa

Detalles Bibliográficos
Autores principales: McCarthy, Michael J., Pagba, Cynthia V., Prakash, Priyanka, Naji, Ali K., van der Hoeven, Dharini, Liang, Hong, Gupta, Amit K., Zhou, Yong, Cho, Kwang-Jin, Hancock, John F., Gorfe, Alemayehu A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2019
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396121/
https://www.ncbi.nlm.nih.gov/pubmed/30842983
http://dx.doi.org/10.1021/acsomega.8b03308

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396121/
https://www.ncbi.nlm.nih.gov/pubmed/30842983
http://dx.doi.org/10.1021/acsomega.8b03308

Ejemplares similares